Published in Blood Weekly, September 30th, 2004
"To determine the feasibility and effectiveness of integrating highly active antiretroviral therapy (HAART) into existing tuberculosis directly observed therapy (TB/DOT) programs, we performed a pilot study in an urban TB clinic in South Africa.
"Patients with smear-positive pulmonary TB were offered HIV counseling and testing," scientists writing in the Journal of Acquired Immune Deficiency Syndromes report.
"Twenty HIV-positive patients received once-daily didanosine (400 mg) plus lamivudine (300...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-09-30)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.